Immutep announces the publication of TACTI-002 and INSIGHT-004



SYDNEY, AUSTRALIA, May 20, 2021 (GLOBE NEWSWIRE) – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, has the Pleased to announce that data from its TACTI-002 and INSIGHT-004 have been published in abstracts available through the links below on the official website of the 2021 American Society of Clinical Oncology (ASCO) 2021 Annual Meeting .

Poster presentations with new and updated data that are not part of the summaries will be available on ASCO.org starting at 9:00 a.m. on June 4, 2021 US Eastern Time and made available on the site. Immutep web at www.immutep.com.

TACTI-002

Title: Results of a phase II study on soluble eftilagimod alpha (LAG-3 protein) and pembrolizumab in patients with unselected PD-L1 metastatic non-small cell lung carcinoma.

Abstract: https://meetinglibrary.asco.org/record/200536/abstract

Title: Results of a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with unselected second-line metastatic squamous cell carcinoma of the head and neck PD-L1.
Abstract: https://meetinglibrary.asco.org/record/197989/abstract

OVERVIEW-004

Title: Phase I INSIGHT Platform Trial: Advanced Safety and Efficacy Data from Stratum D Evaluating the Feasibility and Safety of Soluble Eftilagimod alpha (LAG-3 Protein) Associated with Avelumab in advanced solid tumors.
Abstract: https://meetinglibrary.asco.org/record/200117/abstract

About the American Society of Clinical Oncology (ASCO) Conference
ASCO’s annual meeting represents the world’s largest gathering of medical oncologists, industry representatives, researchers, patient advocates and investment analysts to discuss clinical research and cutting-edge therapies in oncology, and for ideas to improve cancer care. For more information on the ASCO 2021 Annual Meeting, please visit https://www.asco.org/.

About TACTI-002
TACTI-002 (Two ACTive Immunotherapies) is a Phase II clinical trial conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, United States (known as “MSD” outside of the United States and from Canada). The study evaluates the combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in up to 183 patients with squamous cell carcinoma of the head and neck or non-small cell lung cancer at first and second intention.

About INSIGHT-004 (also called INSIGHT Strata D)
INSIGHT-004 is a Phase I clinical trial and is the fourth installment of the investigator-initiated INSIGHT trial which is being conducted by the IKF Clinical Cancer Research Institute at Krankenhaus Nordwest in Frankfurt. It is being conducted as part of Immutep’s collaboration with Merck KGaA and Pfizer Inc., and is evaluating the safety, tolerability and recommended dose of phase II efti when co-administered with avelumab , a human anti-PD-L1 antibody, in 12 cancer patients. Avelumab is co-developed and co-marketed by Merck KGaA, Darmstadt, Germany and Pfizer Inc.

About Immutep
Immutep is a globally active biotechnology company, a leader in the development of immunotherapeutics related to LAG-3 for the treatment of cancer, infectious diseases and autoimmune diseases. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and maximize shareholder value. Immutep is listed on the Australian Securities Exchange (IMM) and NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, which is a first-class antigen-presenting cell (APC) activator currently being explored in the world. cancer and infectious diseases. Immutep is also developing an LAG-3 agonist (IMP761) for autoimmune diseases. Other LAG-3 products, in particular antibodies for modulating the immune response, are under development by Immutep’s major pharmaceutical partners.

Further information can be found on the company’s website www.immutep.com or by contacting:

Australian Investors / Media:
Catherine Strong, Citadelle-MAGNUS
+61 (0) 406 759 268; [email protected]

American media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]



Source link

Previous Sri Lanka's imports surge in March 2021 despite controls like credit, exports resume
Next All politics are local: restructuring transportation projects to be successful in the United States

No Comment

Leave a reply

Your email address will not be published.